News Mylan finalises $465m deal with US government over EpiPen Mylan finalises rebate deal with US government.
News Circassia gives up on allergy treatments after second trial ... UK biotech to focus on respiratory drugs after house dust mite therapy fails.
News Mylan recalls pricey US EpiPens, but cheaper version unaffec... More trouble for embattled Mylan.
News Mylan recalls 81,000 EpiPens after reports of failures Recall follows two reports that allergy injection device failed.
News Circassia shares plummet following cat allergy therapy failu... Company said the failure could have implications for its other products under development
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
